1Hedlund G, Dohlsten M, Petrsson C, et al. Superontigen-based tu rmor theraphy in vivo. activation of cytotoxic T cell. cancer Immunol Immuother 1993,36:89 -91.
2Kugess, Miura Y, Makamura Y, et al. Superantigen induced hunan CD4+ helper/ki ller/ki ller cell and application to tumor immucotheraphy. Immunol, 1995,154(4) : 1775 - 1781.
3Dohosten M, Iamdo PA. Hedlind G, et td. Targeting of human cytotoxic lymphocytes to MHC class Ⅱ -expressing cell by staphylocollal entero toxins. Immuology , 1990,71:96 - 101.
4Dohlsten M, Hedlund G, Sjogren Ho, et al. Two subsets of hceman CD4+ T helper cells differing in kinetics and capacities to produce interleukin-2 and inter feron-gamma can be defined by the leu18 and UCHLI monoclonal. antibodies E UrJ immunol, 1988,18 : 1173 - 1178.
5Lando P, Hedlund G, Dohlston M, et al. Bacterial superatigens as autiture, or agent s: Induction of tumor cytotoxicity is human lymphocytes by staphococal suteroto xin. Cancer mmunol Immuoother.
6Belfrage H, Bhiloadvala P, Hedlund G, et al. Combined activation of murine lymphyol ytes with staphy lococal suterotoxin and interleukin-2 result in adieive cytoto xic activity (I) cancer Immunol Immuother, 1994,38(4) :265 - 361.
7Hasson J, Ericsson Po, Dohlsten M, et al. Loclly saper antigen-activated periton earl eytolytie T lymphocytes belong to - che CD8 + CD45ke subet and lysc MHC class Ⅱ tumor cells. Immunol letter, 1992,24:229- 335.
8Dolsten M, Hedlund C, Akerblom E, et d. Monodonal antibody-targeted saperantige ns: A different class of auti-tumor agents Proc Notl Acad Sci,USA, 1991,88:9287 - 9291.
9Ihle J, Holzer U, Krullf, et al. Antibody targed superantigen induce lysis of maj or histo - compatibilycy complex class 2-negative. T-cell lukemia lines cancer kes, 1995,55:623 - 628.
10Kalland J, Dolsten M, lando P, et al. Targeting of superantigens cell.Biophys, 1993,22( 1 - 3) : 147 - 156.
4Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleund effusions and a survival benefit in non-small cell lung cancer[ J]. Chest, 2004, 126 (5) :1529.
5金伯泉.细胞与分子免疫学[M].北京:北京科学技术出版社,2001:372-374.
6Appel H, Seth NP, Gauthier L, et al. Anergy induction by dimeric TCR ligands[ J]. J Immunol, 2001,166(8) :5279-5285.
7Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Kohne CH, Ehninger G, Schmitz M, Bornhauser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006; 55: 268-276
8Pinzon-Charry A, Schmidt CW, Lopez JA. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res 2006; 8: 402
